Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Phase 2

Terminated

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Gastric Adenocarcinoma
Gastric Cancer

Interventions: Procedure: surgery
Procedure: FDG-PET
Drug: 5-FU
Drug: docetaxel
Drug: capecitabine
Radiation: 3D-CRT
Drug: Irinotecan
Radiation: IMRT

First Posted Date: 2015-06-30

Last Posted Date: 2019-09-11

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 5

Registration Number: NCT02485834

Locations: 🇺🇸
Regional Hematology and Oncology PA, Newark, Delaware, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Englewood Hospital and Medical Center, Englewood, New Jersey, United States

and more 68 locations

A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer

Phase 1

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Sevacizumab
Drug: Irinotecan
Drug: 5-FU
Drug: Leucovorin

First Posted Date: 2015-05-25

Last Posted Date: 2016-04-20

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT02453464

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
The First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Phase 1

Terminated

Conditions: Colorectal Carcinoma
Advanced Cancer
Pancreatic Cancer
Renal Cell Cancer
Uterine
Non Small Cell Lung Cancer
Endometrial

Interventions: Drug: Irinotecan + capecitabine
Drug: Irinotecan
Drug: Temsirolimus
Drug: nivolumab

First Posted Date: 2015-04-22

Last Posted Date: 2018-07-02

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 33

Registration Number: NCT02423954

Locations: 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Clinical Stage III Cutaneous Melanoma AJCC V8
Clinical Stage IV Cutaneous Melanoma AJCC V8
Fallopian Tube Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Metastatic Renal Cell Carcinoma
Ovarian Carcinoma
Pathologic Stage III Cutaneous Melanoma AJCC V8

Interventions: Drug: Carboplatin
Drug: Eribulin
Drug: Fluorouracil
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Capecitabine
Biological: Pembrolizumab
Drug: Olaparib
Biological: Nivolumab
Biological: Ipilimumab
Drug: Selinexor
Drug: Doxorubicin
Drug: Topotecan
Drug: Pemetrexed
Drug: Irinotecan Hydrochloride
Drug: Oxaliplatin
Drug: Leucovorin Calcium

First Posted Date: 2015-04-17

Last Posted Date: 2024-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 221

Registration Number: NCT02419495

Locations: 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson West Houston, Houston, Texas, United States

and more 2 locations